Elan, as part of its restructuring efforts to manage costs and make additional investments in its pipeline, will suspend biologics manufacturing activities and cut approximately 230 positions, or 14% of the company’s workforce. Elan chief executive officer, Kelly Martin, said, “This internal realignment was driven by an assessment of the biopharmaceuticals business completed by Dr. Carlos V. Paya, president of Elan.” The company will realign the R&D organization within the bio...